Menten AI vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 AI cyclic peptide drug discovery with Bristol Myers Squibb collaboration May 2024; $4.15M Khosla/Uncork/Feld-backed using ML+quantum computing for peptide optimization competing with Relay Therapeutics for pharma licensing.
About
Menten AI is a San Francisco-based AI drug discovery company — backed by Y Combinator (W20) with $4.15 million in total funding from Y Combinator, Khosla Ventures, Uncork Capital, Feld Ventures, Mana Ventures, Quain Investments, Society Health, and Volpini Ventures — developing peptide and protein therapeutics using machine learning and quantum computing to design novel cyclic peptide drug candidates for pharmaceutical licensing partnerships, completing a research collaboration with Bristol Myers Squibb in May 2024. Founded in 2018, Menten AI applies advanced AI algorithms for cyclic peptide optimization and protein structure design with a business model centered on licensing proprietary algorithms and drug candidates to pharma partners rather than developing therapeutics through full clinical development.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.